A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
Epidermal growth factor receptor variant III (EGFRvIII) is highly and specifically expressed in a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for GBM. Recently, bispecific antibodies (BsAbs) have shown exciting clinical benefits in cancer immunotherapy. Here,...
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
MDPI AG
2021-06-01
|
| Collection: | Biomedicines |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/2227-9059/9/6/640 |